Combination of fulvic acid and antibiotic for suppression of growth of bacteria resistant to majority of drugs, or treatment of infections caused by them

FIELD: pharmacology.

SUBSTANCE: invention relates to combinations for treatment of infections caused by gram-negative bacteria positive for NDM-1 producing carbapenemase. The combination includes fulvic acid or a salt thereof as an active ingredient and meropenem.

EFFECT: increased effectiveness of treatment, while the synergistic effect of fulvic acid and meropenem is observed.

6 cl, 2 dwg, 5 tbl, 2 ex

 



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention deals with application of composition, which includes hydrolysate of pea protein and/or peptide for obtaining composition for treatment and/or prevention of infection Helicobacter pylori (versions), as well as such compositions (versions). Characterised compositions include lipid, protein and carbohydrate component, in which protein component includes protein source, which consists of pea protein hydrolysate, obtained by hydrolysis with protease, different from chymotrypsin, or from peptides, selected from group, which consists of Xaan-Asp-Phe-Leu-Glu-Asp-Ala-Phe-Asn-Val-Asn-Arg-Xaam and Xaan-Glu-Leu-Ala-Phe-Pro-Gly-Ser-Ala-Gln-Glu-Val-Asp-Arg-Xaam, where each Xaa independently can be any amino acid, and n and m are integer numbers, independently varying from 0-10, where peptide is contained in pea protein hydrolysate, or from both.

EFFECT: claimed inventions make it possible to treat or prevent diseases, caused by Helicobacter pylori infection, and/or diseases, associated with infection Helicobacter pylori in mammals.

17 cl, 2 tbl, 1 ex

FIELD: veterinary medicine.

SUBSTANCE: method comprises subcutaneous administration of antibiotic preparation enroxyl 5% at a dose of 0.1 ml/kg daily one time a day for 7 days and intramuscular administration of homeopathic preparation ovarinin at a dose of 1 ml/kg one time for 4 days, 4-fold.

EFFECT: use of the invention enables to increase the efficiency of treatment, to reduce treatment time and to restore reproductive function of dogs.

2 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medicine and describes pharmaceutical composition, including therapeutically effective quantity of compound, which has the following structure: , where compound in pharmaceutical composition is present in quantity, efficient for treatment or prevention of antibacterial infection in mammalian subject. Methods of obtaining and application of said dosed forms or pharmaceutical compositions are also claimed.

EFFECT: obtaining composition for treatment or prevention of antibacterial infection in mammalian subject.

15 cl, 8 tbl, 5 ex, 4 dwg

FIELD: medicine.

SUBSTANCE: group of inventions refers to veterinary science and is applicable for treating bovine mastitis. What is declared is a nosode for producing a preparation for treating bovine mastitis. That involves taking mastitis milk 1 ml with clinical signs of purulent-catarrhal mastitis, filling it 70° alcohol 9 ml to produce a homogenous solution; the produced solution is diluted to "Д6" with 70° alcohol. What is also declared is a preparation for treating bovine mastitis containing an aqueous-alcoholic solution of components. The components are Belladonna, Sulphur, Apis mellifica, Conium, Phytolacca, Silicea and above nosode in the following proportions, wt %: Belladonna - 5, Sulphur - 20, Apis mellifica - 20, Conium - 10, Phytolacca - 10, Silicea - 5, nosode - 15, aqueous-alcoholic solution up to 100%. What is also declared is a method of treating bovine mastitis involving the intracisternal administration of the preparation. The preparation is administered in a dose of 5-10 ml per 1 animal once a day.

EFFECT: declared group of inventions is highly effective in treating bovine mastitis.

3 cl, 5 tbl, 1 ex

Antimicrobial agent // 2556509

FIELD: medicine.

SUBSTANCE: compound 2-(1'-hydroxy-4'-isopropenyl-1'-methylcyclohexyl-2'-thio)-methylethanoate having structural formula I: is applicable as an antimicrobial agent.

EFFECT: using the compound of formula I possessing antimicrobial activity provides treating infectious processes caused by susceptible organisms.

5 tbl

FIELD: medicine.

SUBSTANCE: claimed group of inventions relates to field of veterinary. Claimed are: vaccine, aimed against actinobacillous pleuropneumonia, including lipopolysaccharide in complex with one or more repeats of ApxI, ApxII and ApxIII toxins, separated from bacterial culture and polymyxin to reduce symptoms of endotoxic shock, caused by lipopolysaccharide, method of obtaining such vaccine, application of polymyxin to reduce endotoxic shock symptoms when vaccine is introduced, in which polymixyn is added into vaccine in dose from 2.6 to 60 mcg/ml.

EFFECT: claimed group of inventions provides effective means and methods to reduce endotoxic shock symptoms, caused by lipopolysaccharide, when vaccine against actinobacillous pleuropneumonia is introduced to animal.

14 cl, 4 tbl, 4 ex

FIELD: veterinary medicine.

SUBSTANCE: complex antibacterial agent for animals, containing a compound from the group of fluoroquinolones and auxiliary substances, characterised in that it additionally comprises a compound from the group of pleuromutilins in an effective amount.

EFFECT: invention is effective against vegetative and spore forms of bacteria, it is harmless, has no allergenic properties, has a stimulating effect on the indices of humoral immune response, and is stable during storage.

6 cl, 9 ex

FIELD: veterinary medicine.

SUBSTANCE: agent comprises enrofloxacin and excipients. The agent additionally comprises humates of peat or sapropel, with the following ratio of the components, wt %: enrofloxacin substance - 0.5; alkaline solution of humates (pH=12-13) - 80; succinic acid - to pH 10-11; propylene glycol - the rest. The agent is administered with the liquid feed once a day for three to five days at a dose of from 0.5 to 1.0 ml per 1 kg of body weight.

EFFECT: manifestation of pronounced therapeutic effect.

5 tbl, 2 ex

FIELD: chemistry.

SUBSTANCE: invention relates to method of obtaining 7-hydroxyroyleanon, possessing antimicrobial action. said method includes extraction of crushed roots of salvia officinalis with 96% ethyl alcohol with further extract evaporation, processing with water, alcohol distillation and processing with hydrophobic solvent or extraction of said raw material with chloroform with further extract processing with water and evaporation; after which target product is extracted from organic phase by transfer into water-soluble phenolates, with processing with sodium hydroxide water solution; alkali solution is washed with chloroform; acidified with hydrochloric or sulphuric acid; obtained sediment is filtered; dried and crushed.

EFFECT: invention is characterised by improved process manufacturability and provides obtaining individual substance with higher antimicrobial activity than previously extracted royleanon derivatives from salvia officinalis.

2 tbl, 6 ex

FIELD: biotechnology.

SUBSTANCE: invention relates to a strain of the pathogen of pseudomonosis of pigs of the collection of Federal state budgetary institution "VGNKI", deposited under the name "Pseudomonas aeruginosa No.9" and the registration number "No.9-DEP", intended for production of a vaccine against pseudomonosis of pigs.

EFFECT: invention provides high immunogenic activity and the ability of production of the vaccine against pseudomonosis of pigs.

4 ex, 3 tbl

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science and consists in a method for cell immunity activation in vitro with homeopathic medicines. A leukocyte suspension 0.5 ml is added with a homeopathic medicine 0.5 ml diluted in normal saline; the prepared solution is placed into a thermostat for 1 hour at T=37±0.5°C; the solution is added with a microbial reference strain Staphylococcus albus No.182 suspension 0.5 ml containing 109 CFU in normal saline 1 ml; the new solution is placed into the thermostat for 30 minutes at T=37±0.5°C; after incubation, blood smears are fixed in alcohol-formalin for 10 minutes and stained according to Romanowsky-Giemsa for 30 minutes.

EFFECT: cell immunity activation.

3 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents a method for reducing extracellular matrix producing cells in lungs or suppressing an increase of the extracellular matrix producing cells in lungs, involving administering into an individual a composition containing (i) a carrier containing retinoid as a targeting agent, and (ii) a pro-drug specified in a group consisting of siRNA, RNA enzyme, anti-sense nucleic acid and DNA/RNA chimeric polynucleotide, which is targeted on HSP47, and vectors expressing said siRNA, RNA enzyme, anti-sense nucleic acid and/or DNA/RNA chimeric polynucleotide.

EFFECT: invention provides using retinoic acid as a targeting agent for the drug delivery to the extracellular matrix producing cells in the lungs.

8 cl, 6 dwg, 3 ex

FIELD: medicine.

SUBSTANCE: what is presented is using a complex of tris-(2-hydroxyethyl)amine and zinc bis-(2-methylphenoxyacetate) [cinkatran or citrimin] of formula: (HOCH2CH2)3N·Zn(OOCCH2OC6H4CH3-2)2 as an agent suppressing total activity of basic (alkaline) mononuclear phospholipase A2.

EFFECT: invention enables extending the range of using the substances as an ingredient of new pharmaceuticals for preventing sclerotic vascular injuries.

2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: what is presented is using a complex of tris-(2-hydroxyethyl)amine with bis-(2-methylphenoxy-acetate)zinc[zincatran or citrimine] of formula: (HOCH2CH2)3N·Zn(OOCCH2OC6H4CH3-2)2 as an acidic phospholipase Al inhibitor.

EFFECT: invention enables extending the substance use as a component of new pharmacological preparations for preventing sclerotic involvement of blood vessels.

1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a combination of sigma-receptor ligand of formula (I) or its pharmaceutically acceptable salt, isomer or solvate, and a chemotherapeutic agent specified in a group formed by taxane, vincaalkaloids, platinum-based drugs and thalidomide. In formula (I), the radicals R1-R6 have the values specified in the patient claim, and n is specified in 2, 3 and 4.

EFFECT: declared combination can be used for preventing or treating pain caused by the above chemotherapeutic agents if administered simultaneously, separately or sequentially.

15 cl, 18 dwg, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and represents using sulphated hyaluronic acid for preparing a therapeutic agent for local administration for treating inflammatory/irritating skin diseases specified in dermatitis, atopic dermatitis, photocontact dermatitis, rash, vitiligo, eczema, psoriasis, all skin irritations related to activation of anti-inflammatory cytokines, such as IL-1, IL-2, IL-7, IL-8, IL-9 and TNF, wherein hyaluronic acid has a molecular weight falling within the ranges of 10000 D to 50000 D, 150000 D to 250000 D and 500000 D to 750000 D, and a sulphatation degree equal to 1.

EFFECT: invention provides stimulating the immune system protein synthesis for eliciting the immune response.

8 cl, 33 ex, 15 dwg, 3 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to immunology. What is presented is a prophylactic or therapeutic agent for IL-31 related itching, containing an effective amount of anti-NR10 antibody, possessing NR10-neutralising (alternative name IL-31RA) activity as an active ingredient, and pharmaceutically acceptable additives, wherein the anti-NR10 antibody represents an antibody, which contains the heavy-chain amino acid sequence SEQ ID NO: 17 and the light-chain amino acid sequence SEQ ID NO: 18, or its humanised antibody. What is presented is using the anti-NR10 antibody containing the heavy- and light-chain amino acid sequences SEQ ID NO: 17 and SEQ ID NO: 18 respectively, or its humanised antibodies for preparing the prophylactic or therapeutic agent for IL-31 related itching. What is described is a method for preventing or treating IL-31 related itching, which involves the stage of administering the anti-NR10 antibody containing the heavy-chain amino acid sequence SEQ ID NO: 17 and the light-chain amino acid sequence SEQ ID NO: 18, or its humanised antibodies.

EFFECT: invention enables suppressing IL-31 overexpression itching.

3 cl, 5 dwg, 2 ex

FIELD: pharmacology.

SUBSTANCE: invention relates to a therapeutical or preventive agent for treatment of hypertension or high blood pressure and to the appropriate method of treatment with its usage. The proposed agent contains (a) and (b) as active ingredients: (a) 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolcarbonic acid (febuxostat) or its pharmaceutically acceptable salt; (b) a compound selected from a group made of blockers of calcium channels, blockers of a receptor of angiotensin II, and inhibitors of an angiotensin-converting ferment and their salts applicable from the point of view of medicine.

EFFECT: synergism of lower blood pressure on a model of spontaneous hypertension.

9 cl, 4 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics and represents a method of treating psoriasis or a related symptoms, in an individual, involving the local administration of a local composition containing a therapeutic effective amount of an α2 adrenergic receptor agonist and a pharmaceutically acceptable carrier on an individual's skin area, wherein the skin area is subject to psoriasis or the related symptom, or prone thereto, and wherein the α2 adrenergic receptor agonist is brimonidine.

EFFECT: invention provides developing the effective and safe method for treating or preventing psoriasis with no side effects or small side effects.

10 cl, 1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, namely to dermatology, and can be used for treating such diseases, as rosacea, psoriasis, topic dermatitis or acne. That is ensured by a local application on an individual's skin area of a topical composition, which can be an ingredient of a kit and contains a therapeutically effective amount of an α2-adrenergic receptor agonist, wherein the α2-adrenergic receptor agonist is specified in a group consisting of: a compound of formula (Ia) wherein each of R1, R2 and R3 independently means hydrogen, halogen, (C1-C8)alkyl or alkoxy; each of R4 and R5 independently means hydrogen, (C1-C8)alkyl or alkoxy; each of R6 and R7 independently means hydrogen, nitro, (C1-C8)alkyl or alkoxy; alkoxy is specified in methoxy, ethoxy, n-propoxy, sec-butoxy, tret-butoxy, n-hexyloxy; and a therapeutically effective amount of the non-steroid anti-inflammatory agent diclofenac and a pharmaceutically acceptable carrier, wherein the skin area is subject to or can be injured by an inflammatory skin disease or a symptom related to the above disease. The α2-adrenergic receptor agonist can be presented by, e.g. brimonidine.

EFFECT: ensuring the synergetic effect when using the declared combination which shows the synergetic effect by improving the anti-inflammatory action of diclofenac that leads to the complete relief of any symptoms of the inflammatory disease.

21 cl, 3 ex, 6 tbl, 2 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely to a method for producing a complex compound of dihydroquercetin with metal ions specified in zinc, copper (II) or calcium possessing antioxidant activity. A method consists in the fact that dihydroquercetin and metal salt is mixed in the dry state in a reactor in certain molar ratio; that is followed by adding water at a certain temperature or ethanol or aqueous-alcoholic solution at a room temperature at the controlled medium acidity; using metal salts containing weak acid anions provides medium pH equal to 5.0-5.6; using the metal salts containing strong acid anions requires reducing pH to 7 by adding an alkaline solution; the reaction is completed almost immediately for the first 5 minutes; the precipitation is filtered in water and/or ethanol; dried in air, then in a drying box to constant weight, and a complex compound is produced. The declared method enables reducing the production costs substantially and cheapening the technological process in achieving the target yield with the preset properties.

EFFECT: method enables producing the stable metal structures and individual powdered substances.

3 cl, 3 dwg, 3 tbl, 12 ex

Up!